Syros Pharmaceuticals (SYRS) Earning Somewhat Favorable Media Coverage, Report Shows

Media stories about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1087773112963 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Several research firms recently issued reports on SYRS. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. BidaskClub lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Wedbush reiterated an “outperform” rating and set a $13.00 price target (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. HC Wainwright reiterated a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. Finally, Oppenheimer set a $28.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $21.13.

NASDAQ SYRS opened at $12.43 on Friday. The company has a market cap of $399.20, a P/E ratio of -5.84 and a beta of -2.83. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Monday, March 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). analysts forecast that Syros Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

In related news, Director Srinivas Akkaraju bought 209,424 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were purchased at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 33.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Insider Buying and Selling by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply